Erythropoietin, darbepoetin, bumetanide
| Erythropoietin | n | Study type | Absorption | VD (L/kg) | Metabolite CL (mL/kg/hour) | CL (mL/kg/hour) | t1/2 (hour) |
| Frymoyer et al70 | 47 | Prospective | / | VC=0.074 VP=0.096 | / | 8.3 | / |
| Wu et al68 | 24 | Prospective | / | 0.095–0.178 | / | 7.7–15.6 CL↓ with dose↑ | / |
| Roberts et al73 | 26 | Prospective | / | 0.511 | / | 15.0 | 23.6 |
| Baserga et al72 | 30 | Prospective | / | / | / | 40.0–50.0 | 24–35 |
| Miscellaneous | |||||||
| Jullien et al81 (Bumetanide) | 14 | Prospective | / | 0.23 | / | 19.8 | 8.4 |
| Pressler et al82 (Bumetanide) | 14 | Prospective | / | 0.23 | / | 19.8 | 8.4 |
| Favié et al74 (2-iminobiotin) | 12 | Prospective | / | VC=0.138 VP=0.368 | / | 113.8 | 2.9 |
AUC, area under the curve; CL, total body clearance; DH, deep hypothermia; HMG, 1-hydroxymidazolam glucuronide; MEGX, monoethylglycinexylidide; MH, moderate hypothermia; NT, normothermia; OHM, 1-hydroxymidazolam; PNA, postnatal age; RCT, randomised controlled trial; t1/2, half life; TH, therapeutic hypothermia; VC, central distribution volume; VD, volume of distribution; VP, peripheral distribution volume.